Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
VIVUS INC (VVUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/16/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date"
07/13/2020 8-K Quarterly results
07/07/2020 8-K Quarterly results
06/19/2020 8-K Quarterly results
06/02/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P. CAMPBELL, CA., June 2, 2020 — VIVUS, Inc. , a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. , which holds a principal amount of approximately $170.2 million of the Company's Convertible Senior Notes."
05/08/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
05/01/2020 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
Docs: "Agreement Regarding Convertible Notes, by and among VIVUS, Inc., the Noteholder and the Trustee",
"VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt CAMPBELL, CA., May 1, 2020 — VIVUS, Inc. , a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company's Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of the agreement, the Company will pay IEH Biopharma $3.8 million in accrued and unpaid interest on the Convertible Senior Notes and IEH Biopharma will grant the Company a 30-day grace period , beginning today, for payment of the p..."
04/03/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules CAMPBELL, CA., April 3, 2020 — VIVUS, Inc. , a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company's common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million, before deducting the placement agent's fees and other offering expenses payable by the Company. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, research and development and satisfaction of corporate debts. The shares of common stock were offered by the Company ..."
04/02/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Form of Placement Agent Warrant",
"Opinion of Hogan Lovells US LLP",
"Form of Securities Purchase Agreement, by and between the Company and the Purchasers",
"Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC"
04/01/2020 8-K Quarterly results
03/31/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”"
03/06/2020 8-K Quarterly results
03/06/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
02/21/2020 8-K Quarterly results
02/19/2020 8-K Quarterly results
02/05/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE with a 36-Month Shelf Life"
01/31/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/07/2020 8-K Quarterly results
12/31/2019 8-K Quarterly results
12/18/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity"
11/20/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa"
11/08/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Transcript of VIVUS, Inc. Third Quarter Ended September 30, 2019 Earnings Conference Call on November 5, 2019, at 4:30 p.m. ET"
11/05/2019 8-K Quarterly results
Docs: "VIVUS Reports Third Quarter 2019 Financial Results Company to host conference call today at 4:30pm ET CAMPBELL, CA., November 5, 2019 - VIVUS, Inc. , a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended September 30, 2019 and provided a business update. “The strategies that we have implemented over the past several quarters continue to gain traction, as evidenced by growing patient adoption rates from our Qsymia Advantage Program, which increased 170% in prescriptions in the third quarter compared with the second quarter,” said John Amos, VIVUS' Chief Executive Officer. “As we implement our plan to expand the U..."
10/28/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors"
10/21/2019 8-K Quarterly results
10/07/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe"
10/03/2019 8-K Quarterly results
09/05/2019 8-K Investor presentation
Docs: "Slide presentation entitled “Investor Presentation September 2019 — Innovate, Deliver and Grow — Nasdaq: VVUS”"
08/27/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019"
08/20/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "New Pilot Clinical Study Results Demonstrate that Addition of VIVUS' Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone"
08/09/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy